Weight loss-related microrna biomarkers and uses thereof

The use of microRNA biomarkers hsa-miR-17-5p, hsa-miR-423-5p, hsa-miR-425-5p, hsa-let-7b-5p, and hsa-miR-93-5p addresses the lack of molecular indicators in obesity treatments, enabling effective prediction and monitoring of weight loss and diabetes treatment responses.

WO2026240578A1PCT designated stage Publication Date: 2026-11-19IND ACADEMIC COOPERATION FOUND KEIMYUNG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2026/096862
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-13
Filing Date
2026-05-12
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing obesity treatments lack molecular-level biomarkers to predict or monitor individual responses to weight loss drugs, and conventional indicators like BMI and blood metabolic markers are insufficient for explaining weight change, early diagnosis, or establishing personalized treatment strategies.

Method used

The use of five specific microRNA biomarkers (hsa-miR-17-5p, hsa-miR-423-5p, hsa-miR-425-5p, hsa-let-7b-5p, and hsa-miR-93-5p) to develop pharmaceutical compositions and methods for predicting and monitoring weight loss and diabetes treatment efficacy, particularly with SGLT2 inhibitors, by measuring their expression levels before and after drug administration.

Benefits of technology

These microRNA biomarkers provide a means to predict and monitor weight loss and diabetes treatment efficacy, offering personalized treatment strategies and improving the effectiveness of obesity management.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2026096862_19112026_PF_FP_ABST
    Figure KR2026096862_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to: five microRNA biomarkers hsa-miR-17-5p, hsa-miR-423-5p, hsa-miR-425-5p, hsa-let-7b-5p, and hsa-miR-93-5p, which are related to weight loss; and uses thereof. The five microRNA biomarkers of the present invention exhibit significant correlations with weight loss and exhibit effects of inhibiting adipocyte differentiation or fat accumulation, and thus can be used to achieve an excellent weight loss effect or predict same.
Need to check novelty before this filing date? Find Prior Art

Description

Weight loss-related microRNA biomarkers and their uses

[0001] The present application claims priority to Korean Patent Application No. 10-2025-0062149 filed on May 13, 2025, and the entire specification is a reference to the present application.

[0002]

[0003] The present invention relates to five microRNA biomarkers associated with weight loss, namely hsa-miR-17-5p, hsa-miR-423-5p, hsa-miR-425-5p, hsa-let-7b-5p and hsa-miR-93-5p, and their uses.

[0004]

[0005] The present invention was completed under project number KH049422 (HR18C0012, 2460004075) with the support of the Ministry of Health and Welfare of the Republic of Korea.

[0006]

[0007] Obesity or overweight is a spreading global public health issue, spreading like an epidemic that affects various age groups and races. Obesity is a multifactorial chronic disease characterized by the excessive accumulation of fat tissue, and it is currently estimated that 70–80% of inter-individual variation is determined by genetic factors. While many obesity treatments are based on dietary therapy, strategies to reduce energy intake or energy efficiency may yield different outcomes and success rates depending on genetic makeup.

[0008] Obesity or overweight is known to increase the risk of developing various chronic diseases, such as type 2 diabetes, cardiovascular disease, fatty liver disease, and some cancers. Accordingly, the development of prevention, diagnosis, and treatment strategies aimed at weight loss or metabolic improvement is actively underway.

[0009] Recently, there has been growing interest in treatments for metabolic diseases that also provide weight loss effects. In particular, SGLT2 (Sodium-glucose cotransporter 2) inhibitors are attracting attention as drugs that significantly reduce weight by inducing calorie loss and acting as a diuretic, while simultaneously lowering blood glucose levels by inhibiting glucose reabsorption. However, individual patient responses to these drugs vary widely, and molecular-level biomarkers capable of predicting or monitoring these responses have not yet been sufficiently established.

[0010] Conventional weight loss monitoring has primarily relied on body mass index (BMI), body fat percentage, or blood metabolic indicators (e.g., blood glucose, insulin, cholesterol levels, etc.), but these indicators have limitations in explaining the molecular causes of weight change, early diagnosis, predicting treatment response, or establishing personalized treatment strategies.

[0011]

[0012] [Prior Art Literature]

[0013] [Patent Literature]

[0014] (Patent Document 1) KR 10-2018-0134336 (2018-11-05)

[0015]

[0016] The inventors made diligent efforts to provide RNA biomarkers associated with weight loss or responsiveness to weight control drugs, and confirmed that five types of microRNA biomarkers of the present invention are closely related to weight loss, thereby completing the present invention.

[0017] Therefore, the object of the present invention is to provide a weight loss-related microRNA biomarker and its uses.

[0018]

[0019] The present invention provides a pharmaceutical composition for the prevention or treatment of obesity comprising hsa-miR-425-5p.

[0020] According to a preferred embodiment of the present invention, the composition additionally comprises hsa-miR-17-5p, hsa-miR-423-5p, hsa-let-7b-5p and hsa-miR-93-5p.

[0021] According to a preferred embodiment of the present invention, the hsa-miR-425-5p is represented by the nucleotide sequence of SEQ ID NO. 3.

[0022] According to a preferred embodiment of the present invention, the hsa-miR-17-5p is represented as the nucleotide sequence of SEQ ID NO. 1, the hsa-miR-423-5p as the nucleotide sequence of SEQ ID NO. 2, the hsa-let-7b-5p as the nucleotide sequence of SEQ ID NO. 4, and the hsa-miR-93-5p as the nucleotide sequence of SEQ ID NO. 5.

[0023] According to a preferred embodiment of the present invention, the obesity is obesity accompanied by diabetes.

[0024] In addition, the present invention provides a composition for weight loss comprising hsa-miR-425-5p.

[0025] According to a preferred embodiment of the present invention, the composition additionally comprises hsa-miR-17-5p, hsa-miR-423-5p, hsa-let-7b-5p and hsa-miR-93-5p.

[0026] In addition, the present invention provides a biomarker composition for predicting the efficacy of a diabetes treatment drug comprising hsa-miR-425-5p.

[0027] According to a preferred embodiment of the present invention, the composition additionally comprises hsa-miR-17-5p, hsa-miR-423-5p, hsa-let-7b-5p and hsa-miR-93-5p.

[0028] According to a preferred embodiment of the present invention, the diabetes treatment is an SGLT2 (sodium glucose cotransporter 2) inhibitor.

[0029] According to a preferred embodiment of the present invention, the efficacy is weight loss efficacy.

[0030] The present invention also comprises the step of (a) measuring the expression level of hsa-miR-425-5p in biological samples derived from a subject before and after administration of a diabetes treatment drug;

[0031] (b) a step of comparing microRNA expression levels before and after administration of the above-mentioned diabetes treatment agent; and

[0032] (c) A step of providing information that the diabetes treatment is effective if the expression level of hsa-miR-425-5p increases after administration of the diabetes treatment;

[0033] A method for providing information on the efficacy of a diabetes treatment drug including

[0034] According to a preferred embodiment of the present invention, the method further measures the expression levels of hsa-miR-17-5p, hsa-miR-423-5p, hsa-let-7b-5p and hsa-miR-93-5p in step (a).

[0035] According to a preferred embodiment of the present invention, the method provides information that if the expression levels of hsa-miR-17-5p, hsa-miR-423-5p, hsa-let-7b-5p and hsa-miR-93-5p increase, there is efficacy as a diabetes treatment agent.

[0036] The present invention also comprises the step of (a) measuring the expression level of hsa-miR-425-5p in biological samples derived from a subject before and after administration of a test substance;

[0037] (b) a step of comparing the microRNA expression levels before and after administration of the test substance; and

[0038] (c) A step of providing information that the composition is for treating obesity or weight loss if the expression level of hsa-miR-425-5p increases after administration of the test substance;

[0039] A screening method for a composition for treating obesity or weight loss comprising

[0040] According to a preferred embodiment of the present invention, the method further measures the expression levels of hsa-miR-17-5p, hsa-miR-423-5p, hsa-let-7b-5p and hsa-miR-93-5p in step (a).

[0041] According to a preferred embodiment of the present invention, the method provides information that the composition is for treating obesity or weight loss when the expression levels of hsa-miR-17-5p, hsa-miR-423-5p, hsa-let-7b-5p and hsa-miR-93-5p increase.

[0042] The present invention also provides a composition comprising hsa-miR-425-5p for use in treating obesity or weight loss.

[0043] According to a preferred embodiment of the present invention, the composition additionally comprises hsa-miR-17-5p, hsa-miR-423-5p, hsa-let-7b-5p and hsa-miR-93-5p.

[0044] The present invention also provides a method for preventing or treating obesity comprising the step of administering hsa-miR-425-5p to an individual in need.

[0045] According to a preferred embodiment of the present invention, the method involves additionally administering hsa-miR-17-5p, hsa-miR-423-5p, hsa-let-7b-5p and hsa-miR-93-5p.

[0046]

[0047] The present invention will be described in more detail below.

[0048]

[0049] The miRNA of the present invention is a sequence derived from the human genome of miRNA, but the miRNA-derived genome is not limited to the human genome and may be a miRNA sequence obtained from another animal genome.

[0050] In the present invention, miRNA can be used as various miRNA mimics that exhibit biologically equivalent effects. For example, a modified miRNA containing a miRNA sequence containing the same seed region can be used.

[0051] In the present invention, miRNAs mimicking miRNAs may partially comprise a phosphorothioate structure in which the RNA phosphate backbone structure is substituted with other elements such as sulfur. Additionally, RNAs wholly or partially substituted with DNA, PNA (peptide nucleic acid), or LNA (lock nucleic acid) molecules may also be used. Furthermore, those obtained by substituting the 2' hydroxyl group of an RNA sugar with various functional structures may also be used. Such modifications include, but are not limited to, methylation, methoxylation, fluorination, etc.

[0052] In the present invention, miRNA is not limited to mature miRNA and double-stranded RNA of miRNA mimics derived therefrom, but can be used in the form of miRNA precursors. miRNA precursors can also be obtained by substituting the RNA phosphate backbone structure described above, by wholly or partially substituting RNA nucleic acid with DNA, PNA, or LNA molecules, or by modifying the 2' hydroxyl group of RNA sugar.

[0053] The present invention may directly include miRNA, or may include a substance capable of enhancing the expression level of said miRNA.

[0054] The substances capable of enhancing the expression level of the above miRNA may be, but are not limited to, saRNA, miRNA, peptide, antibody, aptamer, agonist, natural extract, or chemical substance.

[0055] saRNA (small activating RNA) is a double-stranded RNA of about 19 to 21 base pairs that can mediate RNA activation (RNAa) by binding to the promoter region of a target gene and inducing transcriptional activation, and can increase the transcription of the target gene by inducing epigenetic changes.

[0056] The above "aptamer" refers to a nucleic acid molecule that is a single-stranded oligonucleotide and has binding activity toward a specific target molecule. It has various three-dimensional structures depending on the sequence and can have a high affinity for specific substances, such as in antigen-antibody reactions. By binding to a specific target molecule, the aptamer can inhibit the activity of the specific target molecule. The aptamer of the present invention may be RNA, DNA, modified nucleic acid, or a mixture thereof, and may also be in a linear or cyclic form. The aptamer can be prepared by a person skilled in the art by a known method.

[0057] The term 'prevention' of the present invention refers to any act that causes obesity or obesity-related diseases to be suppressed or their onset to be delayed due to the five types of miRNA biomarkers of the present invention.

[0058] The term 'improvement' or 'treatment' of the present invention refers to any act that causes parameters related to obesity or obesity-related diseases, such as the degree of symptoms, to be improved or benefited by the five miRNA biomarkers of the present invention.

[0059]

[0060] The present invention relates to five microRNA biomarkers associated with weight loss, namely hsa-miR-17-5p, hsa-miR-423-5p, hsa-miR-425-5p, hsa-let-7b-5p and hsa-miR-93-5p, and their uses.

[0061] The present invention tracked changes in exosome-derived miRNA expression while administering SGLT2 inhibitors to patients with type 2 diabetes for 0, 6, and 12 months, and confirmed an increase in the expression of miRNAs associated with weight loss, particularly when administered for more than 12 months. In particular, the expression levels of the five miRNA biomarkers of the present invention increased significantly over time along with a reduction in abdominal visceral fat (VAT). These results suggest that specific miRNAs can act as biomarkers that induce or reflect weight loss, and demonstrate the potential for miRNA-based therapeutic or diagnostic strategies.

[0062]

[0063] Accordingly, the present invention can provide a pharmaceutical composition for the prevention or treatment of obesity comprising hsa-miR-425-5p.

[0064] According to a preferred embodiment of the present invention, the composition may additionally include hsa-miR-17-5p, hsa-miR-423-5p, hsa-let-7b-5p and hsa-miR-93-5p.

[0065] According to a preferred embodiment of the present invention, the hsa-miR-425-5p may be represented by the nucleotide sequence of SEQ ID NO. 3.

[0066] According to a preferred embodiment of the present invention, the hsa-miR-17-5p may be represented as the nucleotide sequence of SEQ ID NO. 1, the hsa-miR-423-5p as the nucleotide sequence of SEQ ID NO. 2, the hsa-let-7b-5p as the nucleotide sequence of SEQ ID NO. 4, and the hsa-miR-93-5p as the nucleotide sequence of SEQ ID NO. 5.

[0067] The above miRNA may include a nucleotide sequence having at least 70%, preferably at least 80%, more preferably at least 90%, and most preferably at least 95% sequence homology with the nucleotide sequence represented by each sequence number.

[0068] The above miRNA may be included in the form of a miRNA precursor, miRNA, an expression vector containing miRNA, or a transformant transformed with said expression vector, but is not limited thereto.

[0069] According to a preferred embodiment of the present invention, the obesity may be obesity accompanied by diabetes.

[0070] The pharmaceutical composition of the present invention may be in various parenteral formulations. When formulating the composition, it may be prepared using one or more buffers (e.g., saline solution or PBS), antioxidants, bacteriostatic agents, chelating agents (e.g., EDTA or glutathione), fillers, extenders, binders, adjuvants (e.g., aluminum hydroxide), suspending agents, thickeners, wetting agents, disintegrants or surfactants, diluents or excipients.

[0071] Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, or suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspensions. Witepsol, macrogol, Tween 61, cocoa paste, laurin paste, glycerol, gelatin, etc. may be used as bases for suppositories.

[0072] The composition of the present invention may be administered parenterally and may be formulated according to methods known in the art in the form of an injectable administered intraperitoneally, rectum, vein, muscle, or subcutaneously.

[0073] The above-mentioned injectable must be sterilized and protected from contamination by microorganisms such as bacteria and fungi. Suitable carriers for the injectable may include, but are not limited to, water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), mixtures thereof, and / or vegetable oils, as solvents or dispersion media. More preferably, suitable carriers may include Hanks' solution, Ringer's solution, PBS (phosphate buffered saline) containing triethanolamine, sterile water for injection, isotonic solutions such as 10% ethanol, 40% propylene glycol, and 5% dextrose. To protect the injectable from microbial contamination, various antimicrobial and antifungal agents such as parabens, chlorobutanol, phenol, sorbic acid, and thimerosal may be additionally included. Additionally, the injectable may, in most cases, further include isotonic agents such as sugars or sodium chloride.

[0074] The composition of the present invention is administered in a pharmaceutically effective amount. A pharmaceutically effective amount refers to an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level may be determined based on factors including the type and severity of the patient's disease, drug activity, sensitivity to the drug, time of administration, route of administration and elimination rate, duration of treatment, concurrently used drugs, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered as a single or multiple doses. That is, the total effective amount of the composition of the present invention may be administered to the patient as a single dose, or administered via a fractionated treatment protocol involving long-term administration of multiple doses. It is important to administer an amount that obtains maximum effect with a minimum amount without side effects by considering all the aforementioned factors, and this can be easily determined by a person skilled in the art.

[0075] The dosage of the pharmaceutical composition of the present invention may vary depending on the patient's weight, age, gender, health condition, diet, time of administration, method of administration, excretion rate, and severity of the disease.

[0076] The composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers.

[0077]

[0078] In addition, the present invention may provide a composition for weight loss comprising hsa-miR-425-5p.

[0079] According to a preferred embodiment of the present invention, the composition may additionally include hsa-miR-17-5p, hsa-miR-423-5p, hsa-let-7b-5p and hsa-miR-93-5p.

[0080] According to a preferred embodiment of the present invention, the hsa-miR-425-5p may be represented by the nucleotide sequence of SEQ ID NO. 3.

[0081] According to a preferred embodiment of the present invention, the hsa-miR-17-5p may be represented as the nucleotide sequence of SEQ ID NO. 1, the hsa-miR-423-5p as the nucleotide sequence of SEQ ID NO. 2, the hsa-let-7b-5p as the nucleotide sequence of SEQ ID NO. 4, and the hsa-miR-93-5p as the nucleotide sequence of SEQ ID NO. 5.

[0082] The above miRNA may include a nucleotide sequence having at least 70%, preferably at least 80%, more preferably at least 90%, and most preferably at least 95% sequence homology with the nucleotide sequence represented by each sequence number.

[0083] The above miRNA may be included in the form of a miRNA precursor, miRNA, an expression vector containing miRNA, or a transformant transformed with said expression vector, but is not limited thereto.

[0084] The above composition may be a pharmaceutical composition, and since this is the same concept as used in the above pharmaceutical composition for the prevention or treatment of obesity, the description is replaced by the description thereof.

[0085]

[0086] In addition, the present invention can provide a biomarker composition for predicting the efficacy of a diabetes treatment drug comprising hsa-miR-425-5p.

[0087] According to a preferred embodiment of the present invention, the composition may additionally include hsa-miR-17-5p, hsa-miR-423-5p, hsa-let-7b-5p and hsa-miR-93-5p.

[0088] According to a preferred embodiment of the present invention, the hsa-miR-425-5p may be represented by the nucleotide sequence of SEQ ID NO. 3.

[0089] According to a preferred embodiment of the present invention, the hsa-miR-17-5p may be represented as the nucleotide sequence of SEQ ID NO. 1, the hsa-miR-423-5p as the nucleotide sequence of SEQ ID NO. 2, the hsa-let-7b-5p as the nucleotide sequence of SEQ ID NO. 4, and the hsa-miR-93-5p as the nucleotide sequence of SEQ ID NO. 5.

[0090] The above miRNA may include a nucleotide sequence having at least 70%, preferably at least 80%, more preferably at least 90%, and most preferably at least 95% sequence homology with the nucleotide sequence represented by each sequence number.

[0091] According to a preferred embodiment of the present invention, the diabetes treatment agent may be an SGLT2 (sodium glucose cotransporter 2) inhibitor.

[0092] According to a preferred embodiment of the present invention, the efficacy may be a weight loss efficacy.

[0093]

[0094] The present invention also comprises the step of (a) measuring the expression level of hsa-miR-425-5p in biological samples derived from a subject before and after administration of a diabetes treatment drug;

[0095] (b) a step of comparing microRNA expression levels before and after administration of the above-mentioned diabetes treatment agent; and

[0096] (c) A step of providing information that the diabetes treatment is effective if the expression level of hsa-miR-425-5p increases after administration of the diabetes treatment;

[0097] A method for providing information on the efficacy of diabetes treatments including can be provided.

[0098] According to a preferred embodiment of the present invention, the method may additionally measure the expression levels of hsa-miR-17-5p, hsa-miR-423-5p, hsa-let-7b-5p and hsa-miR-93-5p in step (a).

[0099] According to a preferred embodiment of the present invention, the method may provide information that an increase in the expression levels of hsa-miR-17-5p, hsa-miR-423-5p, hsa-let-7b-5p and hsa-miR-93-5p indicates efficacy as a diabetes treatment agent.

[0100] The above biological sample may be urine, feces, hair, sweat, saliva, body fluid, blood, cerebrospinal fluid, cells, or tissue, but preferably may be blood.

[0101] According to a preferred embodiment of the present invention, the hsa-miR-17-5p may be represented as the nucleotide sequence of SEQ ID NO. 1, the hsa-miR-423-5p as the nucleotide sequence of SEQ ID NO. 2, the hsa-miR-425-5p as the nucleotide sequence of SEQ ID NO. 3, the hsa-let-7b-5p as the nucleotide sequence of SEQ ID NO. 4, and the hsa-miR-93-5p as the nucleotide sequence of SEQ ID NO. 5.

[0102] The above miRNA may include a nucleotide sequence having at least 70%, preferably at least 80%, more preferably at least 90%, and most preferably at least 95% sequence homology with the nucleotide sequence represented by each sequence number.

[0103] According to a preferred embodiment of the present invention, the diabetes treatment agent may be an SGLT2 (sodium glucose cotransporter 2) inhibitor.

[0104] According to a preferred embodiment of the present invention, the efficacy may be a weight loss efficacy.

[0105]

[0106] The present invention also comprises the step of (a) measuring the expression level of hsa-miR-425-5p in biological samples derived from a subject before and after administration of a test substance;

[0107] (b) a step of comparing the microRNA expression levels before and after administration of the test substance; and

[0108] (c) A step of providing information that the composition is for treating obesity or weight loss if the expression level of hsa-miR-425-5p increases after administration of the test substance;

[0109] A screening method for a composition for treating obesity or weight loss comprising

[0110] According to a preferred embodiment of the present invention, the method may additionally measure the expression levels of hsa-miR-17-5p, hsa-miR-423-5p, hsa-let-7b-5p and hsa-miR-93-5p in step (a).

[0111] According to a preferred embodiment of the present invention, the method may provide information that the composition is for treating obesity or weight loss when the expression levels of hsa-miR-17-5p, hsa-miR-423-5p, hsa-let-7b-5p and hsa-miR-93-5p increase.

[0112] According to a preferred embodiment of the present invention, the hsa-miR-17-5p may be represented as the nucleotide sequence of SEQ ID NO. 1, the hsa-miR-423-5p as the nucleotide sequence of SEQ ID NO. 2, the hsa-miR-425-5p as the nucleotide sequence of SEQ ID NO. 3, the hsa-let-7b-5p as the nucleotide sequence of SEQ ID NO. 4, and the hsa-miR-93-5p as the nucleotide sequence of SEQ ID NO. 5.

[0113] The above miRNA may include a nucleotide sequence having at least 70%, preferably at least 80%, more preferably at least 90%, and most preferably at least 95% sequence homology with the nucleotide sequence represented by each sequence number.

[0114] According to a preferred embodiment of the present invention, the obesity may be obesity accompanied by diabetes.

[0115] The above composition may be a pharmaceutical composition, and since this is the same concept as used in the above pharmaceutical composition for the prevention or treatment of obesity, the description is replaced by the description thereof.

[0116]

[0117] The present invention may also provide a composition comprising hsa-miR-425-5p for use in treating obesity or weight loss.

[0118] According to a preferred embodiment of the present invention, the composition may additionally include hsa-miR-17-5p, hsa-miR-423-5p, hsa-let-7b-5p and hsa-miR-93-5p.

[0119] According to a preferred embodiment of the present invention, the hsa-miR-425-5p may be represented by the nucleotide sequence of SEQ ID NO. 3.

[0120] According to a preferred embodiment of the present invention, the hsa-miR-17-5p may be represented as the nucleotide sequence of SEQ ID NO. 1, the hsa-miR-423-5p as the nucleotide sequence of SEQ ID NO. 2, the hsa-let-7b-5p as the nucleotide sequence of SEQ ID NO. 4, and the hsa-miR-93-5p as the nucleotide sequence of SEQ ID NO. 5.

[0121] The above miRNA may include a nucleotide sequence having at least 70%, preferably at least 80%, more preferably at least 90%, and most preferably at least 95% sequence homology with the nucleotide sequence represented by each sequence number.

[0122] The above miRNA may be included in the form of a miRNA precursor, miRNA, an expression vector containing miRNA, or a transformant transformed with said expression vector, but is not limited thereto.

[0123] According to a preferred embodiment of the present invention, the obesity may be obesity accompanied by diabetes.

[0124]

[0125] The present invention may also provide a method for preventing or treating obesity comprising the step of administering hsa-miR-425-5p to an individual in need.

[0126] The above individuals may include individuals that have already developed obesity or are at risk of developing it. Additionally, the above individuals may include individuals for whom it is necessary to evaluate or predict whether a weight loss effect occurs depending on responsiveness to a diabetes treatment, preferably an SGLT2 inhibitor. The above individuals may refer to all mammals, including but not limited to humans, dogs, cattle, horses, rabbits, mice, rats, or chickens.

[0127] According to a preferred embodiment of the present invention, the method may additionally administer hsa-miR-17-5p, hsa-miR-423-5p, hsa-let-7b-5p and hsa-miR-93-5p.

[0128] According to a preferred embodiment of the present invention, the hsa-miR-425-5p may be represented by the nucleotide sequence of SEQ ID NO. 3.

[0129] According to a preferred embodiment of the present invention, the hsa-miR-17-5p may be represented as the nucleotide sequence of SEQ ID NO. 1, the hsa-miR-423-5p as the nucleotide sequence of SEQ ID NO. 2, the hsa-let-7b-5p as the nucleotide sequence of SEQ ID NO. 4, and the hsa-miR-93-5p as the nucleotide sequence of SEQ ID NO. 5.

[0130] The above miRNA may include a nucleotide sequence having at least 70%, preferably at least 80%, more preferably at least 90%, and most preferably at least 95% sequence homology with the nucleotide sequence represented by each sequence number.

[0131] The above miRNA may be included in the form of a miRNA precursor, miRNA, an expression vector containing miRNA, or a transformant transformed with said expression vector, but is not limited thereto.

[0132] Since the above administration is identical to the concept used in the above pharmaceutical composition, the description is replaced by the description thereof.

[0133] According to a preferred embodiment of the present invention, the obesity may be obesity accompanied by diabetes.

[0134]

[0135] The five types of microRNA biomarkers of the present invention show a significant correlation with weight loss and exhibit an effect of inhibiting adipocyte differentiation or fat accumulation, so they can provide an excellent weight loss effect.

[0136]

[0137] Figure 1 shows the expression levels of five miRNA biomarkers selected in the present invention. It was confirmed that the five miRNAs did not show a significant change at 6 months compared to before taking the SGLT2 inhibitor, but showed a significant increase only at 12 months (paired T-test).

[0138] Figure 2a shows the change in the expression level of miR-425-5p in differentiated adipocytes 3T3-L1 following treatment with a miR-425-5p analog (mimic), as an inhibitory effect of miR-425-5p on adipocyte differentiation and fat accumulation in differentiated adipocytes 3T3-L1.

[0139] Figure 2b shows the change in the expression level of miR-425-5p in differentiated adipocytes 3T3-L1 following treatment with a miR-425-5p inhibitor, as an inhibitory effect of miR-425-5p on adipocyte differentiation and fat accumulation in differentiated adipocytes 3T3-L1.

[0140] Figure 2c shows the change in mRNA expression levels of genes related to adipocyte differentiation and fat accumulation in differentiated adipocytes 3T3-L1 following treatment with a miR-425-5p analog (mimic), as an inhibitory effect of miR-425-5p on adipocyte differentiation and fat accumulation in differentiated adipocytes 3T3-L1.

[0141] Figure 2d shows the change in mRNA expression levels of genes related to adipocyte differentiation and fat accumulation in differentiated adipocytes 3T3-L1 following treatment with a miR-425-5p inhibitor, as an inhibitory effect of miR-425-5p on adipocyte differentiation and fat accumulation in differentiated adipocytes 3T3-L1.

[0142] Figure 2e shows representative images (Oil Red O staining) of intracellular lipid accumulation in differentiated adipocytes 3T3-L1 following treatment with a miR-425-5p mimic or inhibitor, as an inhibitory effect of miR-425-5p on adipocyte differentiation and lipid accumulation in differentiated adipocytes 3T3-L1.

[0143] Figure 2f shows the degree of fat accumulation through quantitative analysis of intracellular fat accumulation images (Oil Red O staining) of differentiated adipocytes 3T3-L1 following treatment with a miR-425-5p analog or inhibitor, as an inhibitory effect of miR-425-5p on adipocyte differentiation and fat accumulation in differentiated adipocytes 3T3-L1.

[0144] Figure 2g shows the inhibitory effect of miR-425-5p on adipocyte differentiation and fat accumulation in differentiated adipocytes 3T3-L1, as well as changes in protein expression levels of genes related to adipocyte differentiation and fat accumulation in differentiated adipocytes 3T3-L1 following treatment with a miR-425-5p mimic or inhibitor (n = 6. *p < 0.05, **p < 0.005 or ***p < 0.001).

[0145]

[0146] The present invention will be described in more detail below through examples. These examples are intended solely to illustrate the present invention, and it is obvious to those skilled in the art that the scope of the present invention is not to be interpreted as being limited by these examples.

[0147]

[0148] [Example 1]

[0149] Patient Selection and Measurement

[0150] <1-1> Study Design and Clinical Parameters

[0151] Twenty-one study participants were recruited at Keimyung University Dongsan Hospital in Daegu, South Korea, from March 2021 to March 2023 to verify changes in microRNA (miRNA) expression within extracellular vesicles (EVs) in the blood via quantitative polymerase chain reaction (qPCR) analysis. This study was approved by the Keimyung University Dongsan Hospital Institutional Review Board (IRB) on September 30, 2021, and all participants provided voluntary informed consent. Study participants diagnosed with type 2 diabetes (T2D) initially took metformin alone, followed by the administration of an SGLT2i for 6 or 12 months after the start of the study.

[0152]

[0153] <1-2> Anthropometric and Clinical Measurement

[0154] Blood was collected from the patient in Example <1-1> at 0 months, 6 months, and 12 months before taking the SGLT2 inhibitor, and clinical indicators were measured.

[0155] Blood samples were collected from each patient using ethylenediaminetetraacetic acid tubes (Becton Drive, Franklin Lakes, NJ, USA). Plasma was separated by centrifuging whole blood at 3,000 ×g for 3 minutes and then stored at -80°C for further analysis. All measurements were performed after fasting overnight for 8 hours. Blood pressure and anthropometric measurements were performed by trained research nurses using standardized protocols. Anthropometric data included height measured using a diameter (FA600, Fanics, Seoul, Republic of Korea). Body weight and composition were assessed using an Inbody 770 (Inbody, Seoul, Korea). Body Mass Index (BMI) was calculated by dividing weight (kg) by the square of height (m). Waist circumference was measured at the midpoint between the lower rib margin and the iliac crest. In addition, reference laboratory data including fasting blood glucose, insulin, glycated hemoglobin (HbA1c), aspartate aminotransferase (AST), alanine aminotransaminase (ALT), creatinine, and lipid profiles were evaluated.The biochemical profiles of blood samples were analyzed using the automated glycated hemoglobin analyzer HLC-723G8 (Tosoh, Tokyo, Japan), the clinical chemistry system analyzer ADVIA2400 (SIEMENS, Munich, Germany), and the BIOSEN C-line clinic (EKF Diagnostic, Barleben, Germany) (BMI, body mass index; HOMA-IR, homeostatic model assessment of insulin resistance; M / C ratio, Microalbumin creatinine ratio; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue; T2DM, type 2 diabetes; S0, 0 months of SGLT2 inhibitor use; S6, 6 months of SGLT2 inhibitor use; S12, 12 months of SGLT2 inhibitor use).

[0156]

[0157] Clinical Information of Measured Patients T2DM+S0 T2DM+S6 T2DM+S12 p-value Number of People (Male / Female) 21 (10 / 11) 21 (10 / 11) 21 (10 / 11) - Age (Years) 58.95±9.76 58.95±9.76 58.95±9.76 - Weight (kg) 72.67±13.19 71.85±13.16 70.41±13.06 0.000 BMI (kg / m² 2)26.70±3.15 26.48±2.9 225.95±2.8 10.001 Waist Circumference (cm) 90.14±8.06 88.00±8.36 86.38±8.16 0.000 Fasting Blood Glucose (mg / dL) 130.81±21.45 118.19±11.99 124.29±24.9 20.045 HbA1C (%) 6.99±0.98 6.69±0.37 6.92±1.14 0.445 Fasting Insulin (μIU / mL) 8.67±6.89-6.52±5.22 0.013 HOMA-IR 2.81±2.06-1.93±1.40 0.011 M / C Ratio (mg / gc Creatinine) 98.10±314.08113.24±279.6495.29±269.710.352 BUN (mg / dL) 17.05±6.79-17.11±5.310.968 Creatinine (mg / mL) 0.84±0.26-0.82±0.250.321 eGFR (mL / min / 1.73m 2 )88.47±24.71-91.15±29.270.357 Systolic Blood Pressure (mmHg) 128.10±11.84 129.24±13.67 122.48±12.560.048 Diastolic Blood Pressure (mmHg) 73.67±11.75 72.29±11.19 69.81±10.100.256 Total Cholesterol (mg / dL) 167.91±40.62-147.66±23.810.138 Triglycerides (mg / dL) 130.35±67.90-147.78±100.840.369 HDL (mg / dL) 50.97±12.81-51.88±13.870.436 LDL (mg / dL)92.65±34.79-75.74±22.250.044 AST (U / L)23.00±6.80-27.00±7.910.143 ALT (U / L)23.81±10.51-28.00±14.650.129 VAT Area (cm²) 2 )157.77±8.47-135.89±7.360.002SAT Area (cm²) 2 )19.60±0.56-19.39±0.58 0.048 Total Body Fat Mass (kg) 24.78±1.20-23.17±1.13 0.001 Total Body Fat Percentage (%) 37.04±1.42-35.90±1.46 0.000 Total Lean Body Mass (kg) 38.95±1.82-39.74±1.9 0.583

[0158]

[0159] As a result, as shown in [Table 1] above, when taking SGLT2 inhibitors for 6 months, there was no significant change in body weight, but a significant decrease in fasting blood glucose and HbA1c was observed. When taking SGLT2 inhibitors for 1 year, it was confirmed that body weight, fasting blood glucose and blood insulin concentration, systolic blood pressure, blood lipids (LDL), visceral fat mass, subcutaneous fat mass, and total fat mass decreased significantly.

[0160]

[0161] [Example 2]

[0162] Measurement of miRNA expression levels

[0163] <2-1> Serum EV-RNA Isolation and Evaluation

[0164] Circulating extracellular vesicles (EVs), i.e., exosomes in the blood, were isolated from serum using ExoQuick isolation reagent (System Bioscience, Palo Alto, CA, USA) according to the manufacturer's instructions. Briefly, the supernatant obtained from the serum sample after centrifugation (3,000×g for 15 minutes) was mixed with ExoQuick reagent and incubated at 4°C for 30 minutes. A second centrifugation was performed at 1,500×g for 30 minutes, and the supernatant was aspirated while maintaining the pellet. The pellet was resuspended in sterile phosphate-buffered saline, and RNA was extracted using the miRNeasy Mini Kit (Qiagen, Hilden, Germany). Purified RNA was obtained through RNA extraction and eluted in RNase-free water (20 μL). The size distribution of EV-RNA was evaluated using an Agilent Bioanalyzer 2100 equipped with an RNA Pico Chip and a Small RNA Chip (Agilent Technologies, Santa Clara, CA, USA). CD63 levels were quantified using the ExoELISA-ULTRA CD63 kit (System Biosciences, Palo Alto, CA, USA) according to the manufacturer's protocol.

[0165]

[0166] <2-2> miRNA Quantification via qRT-PCR

[0167] Approximately 2 ng of purified total EV RNA was reverse transcribed using the TaqMan MiRNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. Pre-amplification was performed by mixing 2.5 μL of cDNA with TaqMan PreAmp Master Mix (Applied Biosystems). Then, quantitative real-time polymerase chain reaction (qRT-PCR) was performed using 9 μL of pre-amplified cDNA, specific TaqMan miRNA Assay probes (Applied Biosystems), and TaqMan universal master mix II under the following thermal cycling conditions: 10 minutes at 95°C, followed by 15 seconds at 95°C and 60 seconds, repeated 40 times. Analysis was completed and data were calculated using Quant Studio Real-time PCR software (hsa, homo sapiens; T2DM, type 2 diabetes; S0, 0 months of use; S6, 6 months of use; S12, 12 months of use).

[0168]

[0169] Levels of miRNA expression in blood exosomes according to duration of SGLT2 inhibitor use in patients with type 2 diabetes Mature miRNA T2DM+S0 T2DM+S6 T2DM+S1 2p-value hsa-let-7b-5P 1.00±0.67 1.25±0.64 2.28±1.97 0.009 hsa-miR-17-5P 1.00±0.62 1.21±0.79 2.52±2.46 0.012 hsa-miR-93-5P 1.00±0.79 1.35±1.12 3.11±2.66 0.002 hsa-miR-423-5P 1.00±0.69 0.99±0.41 1.76±1.13 0.00 1hsa-miR-425-5P1.00±0.861.06±0.882.11±2.090.016hsa-let-7b-3P1.00±2.540.56±1.120.81±1.990.566hsa-let-7d-3P1. 00±0.800.88±0.351.24±1.080.317hsa-miR-24-3P1.00±0.741.02±0.521.66±2.260.227hsa-miR-27a-3P1.00±1.080.88±0.891 .33±1.310.214hsa-miR-103a-3P1.00±1.071.06±1.761.56±2.110.477hsa-miR-150-3P1.00±1.530.88±0.620.98±0.660.803h sa-miR-191-5P1.00±0.980.74±0.441.47±2.160.227hsa-miR-193b-5P1.05±1.572.72±6.470.87±1.150.250hsa-miR-199a-3P 1.00±0.880.67±0.431.39±2.200.221hsa-miR-483-5P1.00±1.881.44±2.451.45±2.490.060hsa-miR-376a-3P1.00±0.990.94± 0.872.01±4.510.282hsa-miR-483-3P1.00±0.541.33±1.291.19±0.990.475hsa-miR-61261.00±0.801.05±0.741.16±0.800.575

[0170]

[0171] [Example 3]

[0172] miRNA biomarker selection

[0173] Based on the results of <Example 2> above, five miRNAs showing significant P-values ​​were selected through statistical analysis (analysis of variance, ANOVA) (Fig. 1).

[0174]

[0175] Spearman correlation analysis between clinical indicators and selected miRNAs VATSAT Total body fat mass Total body fat percentage Lean body mass hsa-let-7b-5P correlation coefficient R-0.453 -0.196 -0.3800.002 -0.437 P-value 0.1040.5030.1800.9940.118 hsa-mi R-17-5P correlation coefficient R-0.532*0.007 -0.3010.088 -0.341 P-value 0.0480.9820.2960.7640.233 hsa-mi R-93-5P correlation coefficient R-0.3760.029-0.2570.046-0.165P-value0.1850.9230.3750.8750.573hsa-miR-423-5P correlation coefficient R-0.535*-0.156-0.437-0.232-0.200P-value0.0460.5940.1180.4260.493hsa-miR-425-5P correlation coefficient R-0.565*-0.090-0.1160.223-0.398P-value0.0350.7590.6920.4440.159

[0176]

[0177] As shown in [Table 3] above, the association between the selected miRNAs and clinical indicators after one year of taking SGLT2 inhibitors was confirmed using the Spearman correlation analysis technique. As a result, among the clinical indicators, the decrease in visceral adipose tissue (VAT) was the only one that showed a significant negative correlation with the increase in expression levels of miR-17-5p, miR-423-5p, and miR-425-5p.

[0178]

[0179] Pearson correlation analysis between clinical indicators and selected miRNAs Body weight BMI Waist circumference Insulin Homa-IRL DL-Cholesterol hsa-let-7b-5P Pearson correlation coefficient R 0.336 -0.369 -0.344 -0.167 -0.100 -0.067 P value 0.137 0.100 0.127 0.49 40.68 30.774 hsa-mi R 17-5P Pearson correlation coefficient R 0.307 -0.349 -0.454 -0.249 -0.177 -0.072 P value 0.176 0.121 0.039 0.30 40.468 0.756 hsa-mi R 93-5P Pearson correlation coefficient R0.184-0.246-0.407-0.305-0.217-0.061P value0.4240.2820.0670.2040.3730.792hsa-miR-423-5P Pearson correlation coefficient R0.198-0.220-0.433-0.080-0.0430.060P value0.3900.3370.0490.7450.8600.796hsa-miR-425-5P Pearson correlation coefficient R0.310-0.348-0.476-0.190-0.133-0.068P value0.1720.1230.0290.4350.5880.769

[0180]

[0181] In addition, as shown in [Table 4] above, the association between the selected miRNAs and clinical indicators after one year of taking SGLT2 inhibitors was confirmed using the Pearson correlation analysis technique. As a result, among the clinical indicators, the decrease in waist circumference was the only one that showed a significant negative correlation with the increase in expression levels of miR-17-5p, miR-423-5p, and miR-425-5p.

[0182] The miRNAs selected based on the results of [Table 3] and [Table 4] above showed significant correlations only with weight loss, waist circumference reduction, and visceral fat reduction among the various effects (body weight, fasting blood glucose and blood insulin concentration, systolic blood pressure, blood lipids (LDL), visceral fat mass, subcutaneous fat mass, and total fat mass) associated with long-term use (12 months) of SGLT2 inhibitors. Through this, the miRNAs can serve as key targets for the mechanism of the weight loss effect of SGLT2 inhibitors. Additionally, the miRNAs can serve as key targets for weight improvement therapeutic agents or therapeutic compositions.

[0183]

[0184] Selected miRNA biomarker sequence information Mature miRNA sequence Sequence number hsa-miR-17-5PCAAAGUGCUUACAGUGCAGGUAG1hsa-miR-423-5PUGAGGGGCAGAGAGCGAGACUUU2hsa-miR-425-5PAAUGACACGAUCACUCCCGUUGA3hsa-let-7b-5PUGAGGUAGUAGGUUGUGUGGUU4hsa-miR-93-5PCAAAGUGCUGUUCGUGCAGGUAG5

[0185]

[0186] [Example 4]

[0187] Fat-reducing effect of selected miRNA

[0188] We intended to investigate the effect of miR-425-5p selected in the above <Example 3> on adipocytes.

[0189] Specifically, the adipocyte cell line 3T3-L1 was differentiated to induce mature adipocytes, then treated with a miR-425-5p analog (mimic; Thermo Fisher Scientific, MC11575) or an inhibitor (inhibitor; Thermo Fisher Scientific, MH11575), and the function was determined using qPCR, Oil Red O staining, or Western blot.

[0190] As a result, the expression level of miR-425-5p in adipocytes was significantly increased compared to the control group (Fig. 2A, p < 0.005). In addition, treatment with a miR-425-5p inhibitor resulted in a significant decrease in the expression level of miR-425-5p in adipocytes compared to the control group (Fig. 2B, p < 0.005).

[0191] In addition, the mRNA expression levels of PPARγ, SREBP1, CEBPα, and ACC1, which are important genes for adipocyte differentiation and fat accumulation, were significantly reduced compared to the control group following miR-425-5p mimic treatment (Fig. 2C), and the mRNA expression levels of PPARγ, SREBP1, CEBPα, and ACC1 were significantly increased compared to the control group following miR-425-5p inhibitor treatment (Fig. 2D).

[0192] Lipid accumulation was significantly reduced compared to the control group following miR-425-5p mimic treatment, and significantly increased compared to the control group following miR-425-5p inhibitor treatment (Figs. 2E and 2F).

[0193] Protein expression levels of PPARγ, SREBP1, CEBPα, and ACC1 also decreased compared to the control group following miR-425-5p mimic treatment, and protein expression levels of PPARγ, SREBP1, CEBPα, and ACC1 increased compared to the control group following miR-425-5p inhibitor treatment (Fig. 2G).

[0194]

[0195] [Statistical Analysis]

[0196] All statistical analyses were performed using SPSS version 27.0 (IBM Co., Armonk, NY, USA). Analysis of clinical parameters before and after SGLT2i administration was performed using paired-sample t-tests or repeated-measures ANOVA. Clinical parameters of the study group were expressed as mean ± standard deviation. EV-miRNA expression levels in T2D patients before and after SGLT2i administration were analyzed using repeated-measures ANOVA. EV-miRNA expression levels were expressed as mean ± standard deviation. Results were considered statistically significant at P < 0.05. Since each miRNA and body composition analysis variable did not follow a normal distribution, Spearman correlation coefficients were used to determine the correlation between miRNA and body composition variables. Since each miRNA and clinical parameter satisfied normality, Pearson correlation analysis was used to analyze the correlation between miRNA and clinical parameters.

[0197]

[0198] The five types of microRNA biomarkers of the present invention exhibit a significant correlation with weight loss and show an effect of inhibiting adipocyte differentiation or fat accumulation, so they can provide an excellent weight loss effect and have industrial applicability.

[0199]

[0200] Sequence number 1 represents the sequence information of hsa-miR-17-5p.

[0201] Sequence number 2 represents the sequence information of hsa-miR-423-5p.

[0202] Sequence number 3 represents the sequence information of hsa-miR-425-5p.

[0203] Sequence number 4 represents the sequence information of hsa-let-7b-5p.

[0204] Sequence number 5 represents the sequence information of hsa-miR-93-5p.

Claims

1. A pharmaceutical composition for the prevention or treatment of obesity comprising hsa-miR-425-5p.

2. A pharmaceutical composition for the prevention or treatment of obesity according to claim 1, characterized in that the composition additionally comprises hsa-miR-17-5p, hsa-miR-423-5p, hsa-let-7b-5p, and hsa-miR-93-5p.

3. A composition according to claim 1, characterized in that the hsa-miR-425-5p is represented by the nucleotide sequence of SEQ ID NO.

3.

4. A composition according to claim 1, characterized in that the above hsa-miR-17-5p is represented by the nucleotide sequence of SEQ ID NO. 1, the above hsa-miR-423-5p is represented by the nucleotide sequence of SEQ ID NO. 2, the above hsa-let-7b-5p is represented by the nucleotide sequence of SEQ ID NO. 4, and the above hsa-miR-93-5p is represented by the nucleotide sequence of SEQ ID NO.

5.

5. A composition according to claim 1, characterized in that the obesity is obesity accompanied by diabetes.

6. A weight loss composition comprising hsa-miR-425-5p.

7. In claim 6, the composition further comprises hsa-miR-17-5p, hsa-miR-423-5p, hsa-let-7b-5p and hsa-miR-93-5p.

8. Biomarker composition for predicting the efficacy of a diabetes treatment containing hsa-miR-425-5p.

9. In claim 8, the composition further comprises hsa-miR-17-5p, hsa-miR-423-5p, hsa-let-7b-5p and hsa-miR-93-5p.

10. A composition according to claim 8, characterized in that the diabetes treatment agent is an SGLT2 (sodium glucose cotransporter 2) inhibitor.

11. A composition according to claim 8, characterized in that the above efficacy is a weight loss efficacy. 12.(a) A step of measuring the expression level of hsa-miR-425-5p in biological samples derived from subjects before and after administration of a diabetes treatment drug; (b) a step of comparing microRNA expression levels before and after administration of the above-mentioned diabetes treatment agent; and (c) A step of providing information that the diabetes treatment is effective if the expression level of hsa-miR-425-5p increases after administration of the diabetes treatment; A method for providing information on the efficacy of a diabetes treatment drug including 13. A method for providing information according to claim 12, characterized in that the method additionally measures the expression levels of hsa-miR-17-5p, hsa-miR-423-5p, hsa-let-7b-5p and hsa-miR-93-5p in step (a).

14. A method of providing information according to claim 13, characterized in that the method provides information that an increase in the expression levels of hsa-miR-17-5p, hsa-miR-423-5p, hsa-let-7b-5p and hsa-miR-93-5p indicates efficacy as a diabetes treatment agent. 15.(a) A step of measuring the expression level of hsa-miR-425-5p in biological samples derived from the subject before and after administration of the test substance; (b) a step of comparing the microRNA expression levels before and after administration of the test substance; and (c) A step of providing information that the composition is for treating obesity or weight loss if the expression level of hsa-miR-425-5p increases after administration of the test substance; A screening method for a composition for treating obesity or weight loss comprising 16. A method according to claim 15, characterized in that the method additionally measures the expression levels of hsa-miR-17-5p, hsa-miR-423-5p, hsa-let-7b-5p and hsa-miR-93-5p in step (a).

17. A method according to claim 16, characterized in that the method provides information that the composition is for treating obesity or weight loss when the expression levels of hsa-miR-17-5p, hsa-miR-423-5p, hsa-let-7b-5p and hsa-miR-93-5p increase.

18. A composition comprising hsa-miR-425-5p for use in treating obesity or weight loss.

19. A composition according to claim 18, characterized in that the composition additionally comprises hsa-miR-17-5p, hsa-miR-423-5p, hsa-let-7b-5p and hsa-miR-93-5p.

20. A method for preventing or treating obesity comprising the step of administering hsa-miR-425-5p to an individual in need.

21. The method of claim 20, characterized in that the method additionally administers hsa-miR-17-5p, hsa-miR-423-5p, hsa-let-7b-5p and hsa-miR-93-5p.